PENGGUNAAN KORTIKOSTEROID PADA SINDROM HELLP

Fakhri Wisa Amrulloh, Ratna Dewi Puspita Sari

Abstract


Background: Hypertension in pregnancy is one of the main causes of maternal morbidity and mortality. HELLP syndrome is potentially life-threatening to the mother. Currently the main treatment for HELLP syndrome is symptomatic. Corticosteroids can be used to treat the patient's condition and promote fetal lung maturation. Methods: The research method used is a literature review, namely literature collected from various sources related to the use of corticosteroids in the HELLP syndrome. Results: The typical clinical symptoms of HELLP syndrome were right upper quadrant abdominal pain, nausea, and vomiting. At less than 27 weeks of gestation, conservative therapy is considered. Corticosteroids are important therapeutic agents used to treat allergic and inflammatory disorders or to suppress unwanted immune systems. Steroid molecules diffuse across cell membranes and bind to glucocorticoid receptors, causing a conformational change in the receptor thereby inhibiting transcription factors that control the synthesis of proinflammatory mediators. Another important effect is the inhibition of phospholipase A2, which is responsible for the production of many inflammatory mediators. Several studies showed that there was no difference in outcome between the treatment group and the control group. Other references say the use of corticosteroids in preterm pregnancy has shown beneficial results. Conclusion: The use of corticosteroids in the HELLP syndrome of preterm pregnancy has been shown to be beneficial.

Keyword: Corticosteroid, HELLP syndrome, Pregnancy


Full Text:

PDF

References


​ACOG. Hypertension in Pregnancy: Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy. Gynecol, Obs. 2013;1122–31.

​Hypertensive Disorders in Pregnancy. Guideline Summary. May 2013. Tersedia dari https//www.health.ny.gov/professionals/protocols_and_guidelines/hypertensive_ Disord akses pada 15 Desember 2021).

​Haram K SE and AU. The HELLP syndrome: clinical issues and management. A Review. BMC Pregnancy Childbirth. 2009;9:8.

​Li Y, Ren C MM. Prognostic factors of the efficacy of high-dose corticosteroid therapy in hemolysis, elevated liver enzymes, and low platelet count syndrome during pregnancy: a meta-analysis. Medicine (Baltimore). 2016;95.

​Jr. MJ. Milestones in the quest for best management of patients with HELLP syndrome (microangiopathic hemolytic anemia, hepatic dysfunction, thrombocytopenia). Int J Gynaecol Obs. 2013;202–7.

​M G. The HELLP syndrome. J Obs Gynaecol. 1997;104:887–91.

​Karumanchi SA, Maynard SE, Stillman IE, Epstein FH SV. Preeclampsia: a renal perspective. Kidney Int. 2005;67:2101–13.

​Magann EF MJJ. Twelve steps to optimal management. Clin Obs Gynecol. 1999(42):532–50.

​Barton JR SB. Diagnosis and management of hemolysis, elevated liver enzymes, and low platelets syndrome. Clin Perinat. 2004;31(807–33).

​Martin JN Jr, Rose CH BC. Understanding and managing HELLP syndrome: the integral role of aggressive glucocorticoids for mother and child. Am J Obs Gynecol. 2006;195:914–34.

​Sibai B. Diagnosis, controversies, and management of the syndrome of hemolysis, elevated liver enzymes, and low platelet count. Obs Gynecol. 2004;103:981–91.

​Koenen SV, Huisjes AJ, Dings J, van der GY, Visser GH BH. Is there a diurnal pattern in the clinical symptoms of HELLP syndrome? J Matern Fetal Neonatal Med. 2006;19:93–9.

​Baxter JK WL. HELLP syndrome: the state of the art. Obs Gynecol Surv. 2004;59:838–45.

​van Runnard Heimel PJ, Franx A, Schobben AF, Huisjes AJ DJ, HW B. Corticosteroids, pregnancy, and HELLP syndrome: a review. Obs Gynecol Surv. 2005;60:57–70.

​Rath W, Faridi A DJ. HELLP syndrome. j Perinat Med. 2000;28:249–60.

​Parnas M, Sheiner E, Shoham-Vardi I, Burstein E, Yermiahu T LI, Holcberg G YR. Moderate to severe thrombocytopenia during pregnancy. Eur J Obs Gynecol Reprod Biol. 2006;128:163–8.

​BM S. Imitators of severe pre-eclampsia/eclampsia. Clin Perinat. 2004;31:835–52.

​Martin JN Jr, Rinehart BK, May WL, Magann EF, Terrone DA BP. The spectrum of severe preeclampsia: comparative analysis by HELLP (hemolysis, elevated liver enzyme levels, and low platelet count) syndrome classification. Am J Obs Gynecol. 1999;180:1373–84.

​Giannubilo SR, Tranquilli AL, Santolini C, Prinicipi F, Mancinelli R L, GP. Placental CoQ10 levels in HELLP syndrome. Biofactors. 2005;25:159–63.

​Haddad, B S. Expectant management of severe preeclampsia: proper candidates and pregnancy outcome. Clin Obs Gynecoll. 2005;48:430–40.

​Gupta P B V. Corticosteroid physiology and principles of therapy. Indian J Pediatr. 2008;75(10):1039–44.

​Ericson-Neilsen W KA. Steroids: pharmacology, complications, and practice delivery issues. Ochsner J. 2014;14(2):203–7.

​DE B. Basic and clinical pharmacology of glucocorticosteroids. Anesth Prog. 2013;60(1):25–31.

​De Wasch K, De Brabander HF, Van De Wiele M, Vercammen J CDIS. Differentiation between dexamethasone and betamethasone in a mixture using multiple mass spectrometry. Wasch K, Brabander HF, Van Wiele M, Vercammen J, Court D. 2001;926:79–86.

​Brownfoot FC, Gagliardi DI, Bain E, Middleton P CC. Different corticosteroids and regimens for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev. 2013;

​Ballard PL BR. Scientific basis and therapeutic regimens for use of antenatal glucocorticoids. Am J Obs Gynecol. 1995;173:254–62.

​Magann EF, Graves GR, Roberts WE, Blake PG, Morrison JC MJJ. Corticosteroids for enhanced fetal lung maturation in patients with HELLP syndrome: impact on neonates. Aust N Z J Obs Gynaecol. 1993;

​Mecacci F, Carignani L, Cioni R, Parretti E MM, Piccioli A D. Time course of recovery and complications of HELLP syndrome with two different treatments: heparin or dexamethasone. Throm Res. 2001;102:99–105.

​Barrilleaux PS, Martin JN Jr, Klauser CK, Bufkin L M, WL. Postpartum intravenous dexamethasone for severely preeclamptic patients without hemolysis, elevated liver enzymes, low platelets (HELLP) syndrome: a randomized trial. Obs Gynecol. 2005;843–8.




DOI: http://dx.doi.org/10.30633/jsm.v5i1.1363

Refbacks

  • There are currently no refbacks.





Publish by Stikes Syedza Saintika Padang 

Contact Person:

Ns. Honesty Diana Morika, M.kep
Editor In Chief
Pusat Penelitian dan Pengabdian Masyarakat
STIKes SYEDZA Saintika Padang

Jl. Prof. Dr. Hamka No. 228 Air Tawar Timur Padang - Sumatera Barat


Phone: 082384992512
Email: lppmsyedza@gmail.com


Google Schoolar